Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apotex Inc.
Apotex’ 505(b)(2) new drug application rival to Alimta will stay off the US market after the Federal Circuit found that a lower court had correctly concluded that prosecution history estoppel did not bar Lilly’s infringement claims against the Canadian firm under the doctrine of equivalents.
Perrigo, Pfizer want FDA to postpone its March deadline for conducting nitrosamine risk assessments. Generics executive cites “serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Executive Decisions: Hardwick Heads US Apotex, Stada Adds To German Management, Lovett Leads Nutrition21 Marketing, More
Hardwick heads Apotex in US; DSM expands cycling team support; Stada adds to Germany management; Lovett leads Nutrition21 marketing; Viatris appoints head of capital markets; and Redcon1 sponsors bodybuilder Greene, wrestler Omega.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
- Drug Delivery
- Generic Drugs
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- ApoPharma, Inc.
- Apotex Australia
- Arrow Pharmaceuticals Pty Ltd.
- Arrow Remedies Private Limited
- Arrotex Australia Group Pty Ltd
- Aveva Drug Delivery Systems, Inc.